Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 9, 2013, Pages 1894-1902

  Mahmood, Kutub ^a   Pelkowski, Sonia ^a   Atherly, Deborah ^a   Sitrin, Robert ^b   Donnelly, John J ^a  

^a PATH   (United States)

^b SitrinSolutions LLC   (United States)

Author keywords

Hexavalent vaccine; Inactivated polio vaccine (IPV); Whole cell acellular Pertussis

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG DESIGN; DRUG MARKETING; HUMAN; PRODUCT DEVELOPMENT; VACCINE PRODUCTION;

HEXAVALENT VACCINE; INACTIVATED POLIO VACCINE (IPV); WHOLE CELL/ACELLULAR PERTUSSIS,;

DEVELOPING COUNTRIES; DIPHTHERIA; HAEMOPHILUS INFECTIONS; HEPATITIS B; HUMANS; POLIOMYELITIS; TETANUS; VACCINES, COMBINED; WHOOPING COUGH;

EID: 84884610082     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25407     Document Type: Article

References (33)

1. World Health Assembly. Global eradication of poliomyelitis by the year 2000 (resolution 41.28). May 1988; Geneva. Available at: http://www.who.int/ihr/ polioresolution4128en.pdf.
2. World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2013; 88:1-16; PMID:23311010
3. Patriarca PA, Sutter RW, Oostvogel PM. Outbreaks of paralytic poliomyelitis, 1976-995. J Infect Dis 1997; 175(Suppl 1):S165-72; PMID:9203711; http://dx.doi.org/10.1093/infdis/175.Supplement-1.S165
4. INFANRIX® hexa (version 4.0). GSK. May 10, 2012. Available at: http://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/362/ FileName/D58F401484B3F7CD68FBC0A2D3A1D77D/Infanrix-Hexa-(Preservative- containing)-v4-0-clean-PDF.pdf.
5. Summary of opinion on hexaxim. European Medicines Agency. June 21, 2012. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Other/2012/ 06/WC500129095.pdf.
6. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730-5; PMID:22423127; http://dx.doi.org/10. 1093/cid/cis287
7. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA 2012; 308:454-6; PMID:22851107; http://dx.doi.org/10.1001/jama.2012.6364
8. Pichichero ME, Green JL, Francis AB, Marsocci SM, Murphy AM, Buscarino C. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine. Scand J Infect Dis 1996; 28:159-63; PMID:8792483; http://dx.doi.org/ 10.3109/00365549609049068
9. Pichichero ME, Rennels MB, Edwards KM, Blatter MM, Marshall GS, Bologa M, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003-11; PMID:15933223; http://dx.doi.org/10.1001/jama.293.24.3003
10. Sturgess AW, Rush K, Charbonneau RJ, Lee JI, West DJ, Sitrin RD, et al. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide. Vaccine 1999; 17:1169-78; PMID:10195629; http://dx.doi.org/10.1016/S0264-410X(98)00337-5
11. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J 2011; 30:e88-96; PMID:21372751
12. Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Chokephaibulkit K, Santos-Lima E. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaPIPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis 2011; 15:e249-56; PMID:21334243; http://dx.doi.org/10.1016/j.ijid.2010.12.004
13. Merck pipeline vaccines. MERCK. February 22, 2013. Available at: http://www.merck.com/research/pipeline/home.html.
14. Diphtheria-tetanus-pertussis (whole cell)-hepatitis b-haemophilus influenzae type b (1 dose vial). World Health Organization. September 7, 2012. Available at: http://www.who.int/immunization-standards/vaccine-quality/07- dtphephib/en/index.html.
15. Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccin Immunother 2012; 8:347-54; PMID:22330958; http://dx.doi.org/10.4161/hv.18630
16. Thalen M, van der Ark A, van den Ijssel J, van Straaten I, Jansen D, Beuvery C, et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 2008; 26:653-63; PMID:18155325; http://dx.doi.org/10. 1016/j.vaccine.2007.11.047
17. Quadrivalent vaccine TAK-361S enters into phase II clinical trials in Japan. Takeda Pharmaceutical Company Limited. 2011. Available at: http://www.takeda.com/news/2011/20111116-3913.html.
18. Quinvaxem®. Crucell. August 15, 2012. Available at: http://www.crucell.com/Products-Quinvaxem.
19. Wyman O. Supply landscape and economics of IPV-containing combination vaccines: key findings. Commissioned by the Bill & Melinda Gates Foundation; 2010. Available at: http://www.polioeradication. org/Portals/0/Document/ Resources/SupplyLandscapeEconomics.09.06.2010.pdf.
20. Sawyer LA, McInnis J, Patel A, Horne AD, Albrecht P. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine 1994; 12:851-6; PMID:7526574; http://dx.doi.org/10.1016/0264-410X(94)90296-8
21. Diphtheria-Tetanus-Pertussis (whole cell)-Haemophilus influenzae type b (10 dose vial). World Health Organization. September 7, 2012. Available at: http://www.who.int/immunization-standards/vaccine-quality/PQ-38-DTPHib-Novartis- 10-dose/en/.
22. Meeting report: WHO Informal Consultation (April 3-4 2012) to develop further guidance on vaccines for UNEP-convened intergovernmental negotiating committee meeting 4 (INC 4). World Health Organization. April 3, 2012. Available at: http://www.who.int/biologicals/Report-THIOMERSAL-WHO-Mtg-3-4-April-2012. pdf.
23. Annex I summary of product characteristics. European Medicines Agency. April 26, 2005. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000298/WC500074586.pdf.
24. Serum Institute of India Ltd. acquires Bilthoven Biologicals of Netherlands. Serum Institute of India Ltd. July 4, 2012. Available at: http://www.seruminstitute.com/content/news-9.htm.
25. GSK and Biological E announce joint venture to develop combination vaccine for India and other developing countries. Business Wire India. January 28, 2013. Available at: http://www.businesswireindia.com/PressRelease.asp?b2mid= 34175.
26. Supplies and logistics: vaccine price data. UNICEF. April 2, 2013. Available at: http://www.unicef.org/supply/index-57476.html.
27. UNICEF. Current IPV supply, recent tender results and outlook for the future. 2012. Available at: http://www.unicef.org/supply/files/IPV-Supply- Status-UNICEFSD-v6.pdf
28. World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2012 - conclusions and recommendations. Wkly Epidemiol Rec 2012; 87:201-16
29. EPI routine vaccines pentavalent, hexavalent and traditional EPI vaccines. UNICEF. January 25, 2012. Available at: http://www.unicef.org/supply/ files/8.-DTP-containing-vaccines-including-pentavalent-and-hexavalent.pdf.
30. VIMS report: global vaccine introduction. International Vaccine Access Center. March 2013. Available at: http://www.jhsph.edu/research/centers-and- institutes/ivac/vims/IVAC-VIMS-Report-2013-03.pdf.
31. Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010; 362:2351-9; PMID:20573923; http://dx.doi.org/10.1056/NEJMoa0909383
32. Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013; 368:416-24; PMID:23363495; http://dx.doi.org/10.1056/NEJMoa1202541
33. Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010; 201:1344-52; PMID:20350164; http://dx.doi.org/10.1086/651611